Home Neoplasma 2016 Neoplasma Vol.63, No.1, p.10-17, 2016

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.63, No.1, p.10-17, 2016

Title: Current antiangiogenic agents in oncology and ophthalmology

Abstract: Antiangiogenic drugs are approved for many cancer types for longer than a decade. Furthermore, several antiangiogenic agents are approved for local application in ophthalmology for treatment of macular degeneration, venous retinal occlusion and diabetic retinopathy. Knowing that antiangiogenic agents are active in ocular system, we reviewed the current literature, whether antiangiogenic drugs may cause ocular side effects in cancer patients by systemic application.
Furthermore, we searched in published papers, if systemic application of antiangiogenic agents in cancer patients may simultaneously treat their ocular disorders, if they have such.
Finally, we emphasized cooperation between an oncologist and ophthalmologist when treating patients with antiangiogenic drugs. 

Keywords: angiogenesis inhibitors, vascular diseases, eye, drug-related side effects and adverse reactions
Published online: 19-Aug-2015
Year: 2016, Volume: 63, Issue: 1 Page From: 10, Page To: 17

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.